Reneo Pharmaceuticals Earnings Reports

In Q2 2025, Reneo Pharmaceuticals experienced an increase in operating expenses due to advancing clinical trials and higher personnel costs. Despite the growing investment in R&D, the company maintains a strong cash position of $83.4 million to support operations into Q4 2026. The net loss widened to $15.4 million, or $1.14 per share.

OnKure Therapeutics reported a net loss of $15.9 million for the first quarter of 2025, with cash and cash equivalents of $96.7 million. The company is advancing its PIKture-01 trial and expects to announce a new pan-mutant selective development candidate in Q2 2025.

OnKure Therapeutics reported a net loss of $17.4 million for the fourth quarter of 2024, with cash and cash equivalents of approximately $110.8 million. The company highlighted progress in its PIKture-01 trial and plans for a pan-mutant program.

Reneo Pharmaceuticals reported a net loss of $5.4 million, or $0.16 per share, during the second quarter of 2024. The company had $76.7 million in cash, cash equivalents, and short-term investments as of June 30, 2024. A merger agreement with OnKure, Inc. was entered into, expected to close in the second half of 2024.

Reneo Pharmaceuticals reported a net loss of $19.2 million, or $0.57 per share, for the third quarter of 2023. The company had $125.6 million in cash, cash equivalents, and short-term investments as of September 30, 2023. Topline data results from the pivotal STRIDE study are expected in December 2023.

Reneo Pharmaceuticals reported a net loss of $19.5 million, or $0.65 per share, for the second quarter of 2023. The company's cash, cash equivalents, and short-term investments totaled $142.7 million as of June 30, 2023. They raised $68.3 million in gross proceeds from a public offering and concurrent private placement of common stock.

Reneo Pharmaceuticals reported a net loss of $13.0 million, or $0.53 per share, for the three months ended September 30, 2022. The company had approximately $116 million in cash, cash equivalents and short-term investments as of September 30, 2022. They have achieved over 80% enrollment in the ongoing pivotal STRIDE study in primary mitochondrial myopathy (PMM) patients with mitochondrial DNA (mtDNA) defects and remain on track to announce topline data from this study in the fourth quarter of 2023.

Reneo Pharmaceuticals reported a net loss of $12.3 million, or $0.50 per share, for the three months ended June 30, 2022. The company had approximately $127 million in cash, cash equivalents and short-term investments as of June 30, 2022.

Reneo Pharmaceuticals reported a net loss of $12.7 million, or $0.52 per share, for the three months ended September 30, 2021. The company's cash, cash equivalents and short-term investments totaled $157.7 million as of September 30, 2021.

Reneo Pharmaceuticals reported a net loss of $9.2 million, or $0.43 per share, for the three months ended June 30, 2021. The company had $167.3 million in cash, cash equivalents and short-term investments as of June 30, 2021.

Reneo Pharmaceuticals reported a net loss of $7.2 million, or $3.48 per share, for the three months ended March 31, 2021. The company had $91.2 million in cash and cash equivalents as of March 31, 2021.